Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: Boston MA, New York NY, New Brunswick NJ, Montreal,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Sex: All
Age: 18+
Code: NCT06297226
Phase2, Recruiting
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
for
Acute Leukemia, Acute Myeloid Leukemia,
Location: Minneapolis MN
Sponsor: Masonic Cancer Center, University of Minnesota
Sex: All
Age: 0 - 60
Code: NCT03314974
Phase2, Recruiting
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
for
Multiple Myeloma
Location: Boston MA
Sponsor: Boston Medical Center
Sex: All
Age: 18+
Code: NCT00898235
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
for
Multiple Myeloma
Location: Elizabeth City NC, Newark DE, Columbia MD, Fairfax VA,
Sponsor: SCRI Development Innovations, LLC
Sex: All
Age: 18+
Code: NCT05972135
Phase2, Recruiting
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
for
Multiple Myeloma
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center
Sex: All
Age: 60+
Code: NCT06679829
Phase2, Recruiting
Dose-escalation Study of Oral CX-4945
for
Advanced Solid Tumors, Breast Cancer,
Location: Houston TX, Fort Collins CO, Loveland CO, Scottsdale AZ
Sponsor: Cylene Pharmaceuticals
Sex: All
Age: 18+
Code: NCT00891280
Phase1, Recruiting
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
for
Multiple Myeloma
Location: New York NY, Birmingham AL, Nashville TN, Milwaukee WI,
Sponsor: University of Alabama at Birmingham
Sex: All
Age: 18+
Code: NCT05231629
Phase2, Recruiting
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
for
Multiple Myeloma, Lymphoma, Non-Hodgkin,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 70+
Code: NCT02682667
Recruiting
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
for
Relapsed or Refractory Multiple Myeloma
Location: Boston MA, New York NY, Hillsborough NC,
Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Sex: All
Age: 18+
Code: NCT06375044
Phase1, Recruiting
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
for
Lymphoproliferative Disorder, Multiple Myeloma
Location: Jacksonville FL, La Crosse WI, Eau Claire WI,
Sponsor: Mayo Clinic
Sex: All
Age: 18+
Code: NCT06630104
Recruiting
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
for
Hematologic Malignancy, Large B-cell Lymphoma,
Location: Los Angeles CA
Sponsor: Joshua Sasine, MD, PhD
Sex: All
Age: 18 - 70+
Code: NCT05887167
Phase1, Recruiting
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
for
Multiple Myeloma
Location: Philadelphia PA, San Antonio TX
Sponsor: Immune Control
Sex: All
Age: 18+
Code: NCT00821301
Phase1, Recruiting
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
for
Plasma Cell Dyscrasias,
Location: Columbus OH
Sponsor: Ohio State University Comprehensive Cancer Center
Sex: All
Age: 18+
Code: NCT01408225
Recruiting
Registry of Older Patients With Cancer
for
Chronic Myeloproliferative Disorders,
Location: Morehead City NC, New Bern NC, Greenville NC,
Sponsor: UNC Lineberger Comprehensive Cancer Center
Sex: All
Age: 65+
Code: NCT01137825
Recruiting
Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
for
Multiple Myeloma
Location: Chicago IL
Sponsor: University of Illinois at Chicago
Sex: All
Age: 18+
Code: NCT05192122
Phase1, Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
for
Multiple Myeloma
Location: Providence RI, Farmington CT, New Haven CT, Lebanon NH,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT05552222
Phase3, Recruiting
A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients
for
Multiple Myeloma
Location: Little Rock AR
Sponsor: University of Arkansas
Sex: All
Age: 18 - 70+
Code: NCT01314625
Recruiting
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function